Tofisopam

When ATH:
N05BA23

Characteristic.

"Full-time" anxiolytic agent, atypical benzodiazepine derivative (2,3-benzodiazepine). White to yellowish white crystalline powder. Practically insoluble in water, it is soluble in alcohol.

Pharmacological action.
Anxiolytic.

Application.

Neuroses and neurosis-like states; states, accompanied by emotional stress, autonomic disorders, moderately severe pain, apatieй, reduced activity, intrusive experiences; reactive depression with moderately severe psychopathological symptoms; post traumatic stress disorder; disorder of mental adaptation; kardialgija (alone or in combination with other drugs), menopause (as an independent means, as well as in combination with hormonal therapy); premenstrual tension syndrome; myasthenia, myopathies, neurogenic muscle atrophy and other pathological conditions with secondary neurotic symptoms, when anxiolytics contraindicated with severe muscle relaxant action.

B narkologii: alcohol withdrawal syndrome, delirious state (for de-excitation and vegetative symptoms), opium withdrawal symptoms and postabstinentnom state. Neurotic, psychotic disorders in alcoholism, and the state, characterized by apathy, reduced activity in alcoholism.

Contraindications.

Hypersensitivity (incl. other benzodiazepines), psychosis and psychopathy with severe psychomotor agitation, aggressiveness or deep depression; decompensated respiratory failure, syndrome, sleep apnea (history), pregnancy (I trimester), breast-feeding, Age to 18 years.

Restrictions apply.

Decompensated chronic respiratory distress syndrome, acute respiratory failure history, zakrыtougolynaya glaucoma, epilepsy, organic brain damage (such as atherosclerosis).

Side effects.

From the nervous system and sensory organs: psychomotor agitation, irritability, aggressiveness, hypererethism, somnipathy.

From the digestive tract: nausea, gastralgia, dyspepsia.

Allergic reactions: itching, rash.

Cooperation.

Deprimiruyuschie funds increase (mutually) CNS depression. Metoclopramide accelerates the onset of effect (It increases the absorption rate due to increased intestinal motility).

Overdose.

Symptoms: deep sleep, in severe cases - coma.

Treatment: recovery of lung function and cardiovascular activity.

Dosing and Administration.

Inside. The mode set individually depending on the evidence, of the patient, tolerability. Single dose - 50-100 mg, the average daily - 150-300 mg 1-3 reception, maximum - 300 mg / day for 4-12 weeks, including the time of gradual withdrawal of the drug. In the elderly and patients with renal insufficiency dose reduced 2 times.

Precautions.

When an allergic reaction or severe sleep disorders should be discontinued. To prevent sleep disorders is recommended to take the drug last time no later than 15-16 hours.

When the affective state of shock and deep depression monotherapy is not recommended, tk. possible masking of symptoms and difficulty of diagnosis. Permanent medical supervision is required when administered to patients with myasthenia gravis and the like.

Tofisopam does not significantly reduce the ability to concentrate. The possibility of vehicle management decided after assessing the individual patient's response to drug.

Cooperation